Free Trial
OTCMKTS:NSPX

Inspyr Therapeutics (NSPX) Stock Price, News & Analysis

About Inspyr Therapeutics Stock (OTCMKTS:NSPX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
29.64 million shs
Average Volume
13.19 million shs
Market Capitalization
$1.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Receive NSPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inspyr Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NSPX Stock News Headlines

EWTX Edgewise Therapeutics, Inc.
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
See More Headlines

NSPX Stock Analysis - Frequently Asked Questions

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) issued its quarterly earnings results on Monday, August, 14th. The company reported ($26.25) earnings per share (EPS) for the quarter.

Shares of Inspyr Therapeutics reverse split before market open on Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inspyr Therapeutics investors own include Stem (STEM), Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Blink Charging (BLNK), BIO-key International (BKYI) and BIOLASE (BIOL).

Company Calendar

Last Earnings
8/14/2017
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:NSPX
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Net Income
$-6,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.07) per share

Miscellaneous

Free Float
N/A
Market Cap
$1.47 million
Optionable
Not Optionable
Beta
-17.33
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:NSPX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners